ClinicalTrials.gg
RecruitingNCT06633016Updated Jan 20, 2026

Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

A Phase 2 interventional study of ABX-002 and Placebo in Major Depressive Disorder, sponsored by Autobahn Therapeutics, Inc.. Recruiting at 50 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Autobahn Therapeutics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Planned enrollment
314th of 1,323
230 · median 70
Started
2024
with 69 others
Phase 2
271 of 1,500
45 open now
Primary completion
2026-06
later than 24 of 258 live
Registered
1,355th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 314th largest by planned enrollment of the 1,323 interventional ones that give a count, is one of 70 that started in 2024, is one of 271 in phase 2, reaches primary completion later than 24 of the 258 other live ones, and was the 1,355th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant.

This is a double-blind, placebo-controlled, 2-arm, parallel-group, Phase 2 study, randomized 1:1 (ABX-002: placebo).

The study will include the following stages:

  1. Screening, approximately 35 days
  2. 42-day Treatment Period
  3. 2-week post dose Safety Follow-up Period
  4. 6-month postdose targeted safety follow-up period
03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets the criteria for Major Depressive Disorder, with a current major depressive episode duration of > 6 weeks and ≤ 18 months.
  • A score of ≤ 22 (midrange mild/moderate) on the Hamilton Anxiety Rating Scale.
  • Montgomery-Asberg Depression Rating Scale total score of > 24 [indicating moderate to severe depression] at Screening and at Baseline.
  • Subject is compliantly using a single selective serotonin reuptake inhibitors / serotonin norepinephrine reuptake inhibitor antidepressant for at least 6 weeks for their current episode of depression, with an adequate dose, and with an inadequate response as defined by the Antidepressant Treatment Response Questionnaire. The dosage of the current antidepressant must have been stable for the past 4 weeks, and the dosage and specific antidepressant used should remain the same from Screening through the end of the Follow-up Period.

Exclusion criteria

Exclusion Criteria:

Note: History implies lifetime history, unless otherwise specified

  • History of schizophrenia or other psychotic disorder, major depressive disorder with psychotic features or concomitant depressive disorders, bipolar I or II disorder, cyclothymic disorder, delirium, dementia, amnestic disorder, or cognitive disorder.
  • Current diagnosis or active symptoms within the last 2 years of obsessive-compulsive disorder, posttraumatic stress disorder, panic disorder, or eating disorder, according to DSM-5 criteria.
  • Primary diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder, according to DSM-5 criteria. Current or history within the last 2 years of self-injurious behavior is exclusionary.
  • Has failed more than 2 single selective serotonin reuptake inhibitors / serotonin norepinephrine reuptake inhibitor antidepressant treatments, including the current serotonin reuptake inhibitors / serotonin norepinephrine reuptake inhibitor, during the current depressive episode, despite an adequate dose (per Antidepressant Treatment Response Questionnaire) and duration (at least 6 weeks).
  • Failure to respond to triiodothyronine or thyroxine augmentation for the treatment of depression.
  • Started new psychotherapy or had a change in the intensity of psychotherapy within 8 weeks before Screening.
  • Is suicidal at Screening or Baseline
  • History or current evidence within previous 3 months before Screening of uncontrolled, neurological, gastrointestinal, respiratory, renal, hepatic, immunological, hematological, or other medical disorder, including cancer, that would jeopardize the safe participation of the subject in the study (in the opinion of the Investigator).
  • History of thyroid disease
  • History of multiple endocrine neoplasia syndrome
  • Diagnosis of epilepsy or history of convulsions, including childhood febrile seizure. Use of co-administered drugs that may lower seizure threshold is excluded.
  • Females who are pregnant, intend to become pregnant or are breastfeeding.
  • Antidepressants: Prior use of psychedelics, ketamine, or esketamine, for the treatment of Major Depressive Disorder.
  • Antidepressants: Current use, or use within 4 weeks prior to Screening, of any other augmentation agents for Major Depressive Disorder (e.g. second-generation antipsychotics [SGA], monoamine oxidase inhibitors [MAOI], tricyclic antidepressants [TCA], lithium, or bupropion)
  • Current or prior use of treatment for hypothyroidism including but not limited to synthetic or natural thyroid hormone, triiodothyronine and/or thyroxine.
  • Concomitant use of biotin of any dose and in any preparation 14 days prior to Day 1 until after the last study visit at Week 8 (Day 56).
  • Medications that are strong cytochrome P450 3A4 inhibitors or strong cytochrome P450 3A4 inducers are not allowed.
  • Prescription drug/controlled substance abuse, or illicit substance use within 1 year of Screening or positive urine drug results at Screening or Baseline for an illicit substance.
  • History or presence of cataract on ophthalmic examination (including slit-lamp), glaucoma, inflammatory eye disease or prior ophthalmic surgical procedures or laser surgery in either eye
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    ABX-002 + SSRI/SNRI

    Patients continue to receive their selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study in addition to ABX-002.

    Drug: ABX-002

  • Placebo comparator
    Placebo + SSRI/SNRI

    Patients continue to receive their selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study in addition to the Placebo.

    Other: Placebo

Interventions

  • ABX-002 oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.

  • OtherPlacebo

    Comparator Placebo oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in the 17-item Hamilton Rating Scale for Depression (HAMD-17)

    The HAMD-17 is a clinician-based assessment of depressive symptoms. Higher scores indicate worse symptoms. A score of 0-9 is generally accepted to be within the normal range (or in clinical remission), while a score of greater than 17 indicates moderate to severe depression symptoms.

    Time frame: 6 weeks

Secondary outcomes

  1. Change from Baseline for Clinical Global Impression of Severity (CGI-S)

    a 7-point rating scale used to measure illness and symptom severity in subjects with mental disorders. The greater the number the more severe.

    Time frame: 6 weeks

  2. Change from Baseline for Sheehan Disability Scale (SDS)

    Self-rated, 3-item questionnaire that uses a Likert scale from 0 (not at all) to 10 (extremely) to assess impairment in the occupational, social, and family domains.

    Time frame: 6 weeks

  3. Change from baseline for 6-item Hamilton Rating Scale for Depression (HAMD-6)

    Six-item scale used to assess the core symptoms of depression.

    Time frame: 6 weeks

  4. Change from baseline for 29-item Hamilton Rating Scale for Depression (HAMD-29)

    Clinician-based assessment of depressive symptoms. HAMD-29 covers HAMD-6, HAMD-17 (items 1 to 17), the Melancholia Scale (MES) (items 18 to 23), and the neurovegetative symptoms (NVS) (items 24 to 28).

    Time frame: 6 weeks

  5. Patient Global Impression-Improvement (PGI-I)

    Quality-of-life questionnaire to assess improvement of activities of daily living, wellbeing, and function.

    Time frame: 6 weeks

  6. Assessment of safety and tolerability of ABX-002 compared with placebo using adverse events

    Incidence and severity of treatment-emergent adverse events to ABX-002 will be measured

    Time frame: 6 weeks

07

Study locations

32 of 50 sites recruiting
  • Autobahn Site #131
    Birmingham, Alabama 35294, United States
    Recruiting
  • Autobahn Site #132
    Chandler, Arizona 85224, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Autobahn Site #116
    Phoenix, Arizona 85102, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Autobahn Site #136
    Tucson, Arizona 85704, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Autobahn Site #150
    Anaheim, California 92805, United States
    Recruiting
  • Autobahn Site #113
    Encino, California 91316, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Autobahn Site #133
    Encino, California 91316, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Autobahn Site #124
    Glendale, California 91206, United States
    Recruiting
  • Autobahn Site #140
    Long Beach, California 90807, United States
    Recruiting
  • Autobahn Site #121
    Los Alamitos, California 90720, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Autobahn Site #117
    Newport Beach, California 92660, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Autobahn Site #106
    Oceanside, California 92056, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Autobahn Site #152
    Orange, California 92866, United States
    Recruiting
  • Autobahn Site #151
    Rancho Cucamonga, California 91730, United States
    Recruiting
  • Autobahn Site #119
    San Jose, California 95124, United States
    Recruiting
  • Autobahn Site #126
    Walnut Creek, California 94596, United States
    Recruiting
  • Autobahn Site #149
    West Covina, California 91790, United States
    Recruiting
  • Autobahn Site #122
    Cromwell, Connecticut 06416, United States
    Recruiting
  • Autobahn Site #108
    Brandon, Florida 33511, United States
    Recruiting
  • Autobahn Site #110
    Hialeah, Florida 33012, United States
    Recruiting
  • Autobahn Site #101
    Jacksonville, Florida 32256, United States
    Recruiting
  • Autobahn Site #139
    Lake City, Florida 32055, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Autobahn Site #111
    Miami, Florida 33144, United States
    Recruiting
  • Autobahn Site #141
    Miami, Florida 33157, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Autobahn Site #147
    Miami Gardens, Florida 33014, United States
    Recruiting
  • Autobahn Site #102
    Orlando, Florida 32822, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Autobahn Site #148
    Tampa, Florida 33629, United States
    Recruiting
  • Autobahn Site #123
    Atlanta, Georgia 30328, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Autobahn Site #112
    Decatur, Georgia 30030, United States
    Recruiting
  • Autobahn Site #142
    Peachtree Corners, Georgia 30071, United States
    Recruiting
  • Autobahn Site #120
    Savannah, Georgia 31405, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Autobahn Site #154
    Elgin, Illinois 60123, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Autobahn Site #137
    Boston, Massachusetts 02130, United States
    Recruiting
  • Autobahn Site #138
    Watertown, Massachusetts 02472, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Autobahn Site #127
    Saint Charles, Missouri 63304, United States
    Recruiting
  • Autobahn Site #130
    Las Vegas, Nevada 89121, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Autobahn Site #129
    Berlin, New Jersey 08009, United States
    Recruiting
  • Autobahn Site #105
    Brooklyn, New York 11229, United States
    Recruiting
  • Autobahn Site #134
    Brooklyn, New York 11235, United States
    Recruiting
  • Autobahn Site #125
    New York, New York 10022, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Autobahn Site #104
    Staten Island, New York 10314, United States
    Recruiting
  • Autobahn Site #109
    Beachwood, Ohio 44122, United States
    Recruiting
  • Autobahn Site #107
    Oklahoma City, Oklahoma 73112, United States
    Recruiting
  • Autobahn Site #128
    North Charleston, South Carolina 29405, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Autobahn Site #153
    Beaumont, Texas 77701, United States
    Recruiting
  • Autobahn Site #146
    San Antonio, Texas 78215, United States
    Recruiting
  • Autobahn Site #144
    Sherman, Texas 75092, United States
    Recruiting
  • Autobahn Site #159
    Orem, Utah 84058, United States
    Recruiting
  • Autobahn Site #145
    Fairfax, Virginia 22030, United States
    Recruiting
  • Autobahn Site #143
    Bellevue, Washington 98007, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jun 2026, 21 months after the start.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's planned 21 months is above that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2024
First posted
Oct 9, 2024
StartActual
Sep 20, 2024
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06633016
Lead sponsor
Autobahn Therapeutics, Inc.
Responsible party
Sponsor
First posted
Oct 9, 2024
Start date
Sep 20, 2024
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Jan 20, 2026

Study contacts

Ashlee Heldreth, MS
Contact
clinicaltrials@autobahntx.com
8582573418

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elunetirom

Start the discussion